Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 16, 2022

Tislelizumab vs Docetaxel in Previously Treated NSCLC

Journal of Thoracic Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Thoracic Oncology
Tislelizumab versus docetaxel in patients with previously treated advanced non-small cell lung cancer (RATIONALE-303): a phase 3, open-label, randomized controlled trial
J Thorac Oncol 2022 Sep 29;[EPub Ahead of Print], C Zhou, D Huang, Y Fan, X Yu, Y Liu, Y Shu, Z Ma, Z Wang, Y Cheng, J Wang, S Hu, Z Liu, E Poddubskaya, U Disel, A Akopov, M Dvorkin, W Zheng, Y Ma, Y Wang, S Li, C Yu, G Rivalland

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading